Humedix Co

Humedix Co EBIT Margin

The EBIT Margin (Operating Margin) of Humedix Co (200670.KQ) as of Oct 17, 2026 is 24.89 %. In the previous year, EBIT Margin (Operating Margin) was 26.65 % — a change of -6.60% (lower).

EBIT Margin

24.89 %

YoY

-6.60%

Last updated:

EBIT Margin (Operating Margin) of Humedix Co is 2025 24.89 % . EBIT Margin (Operating Margin) of Humedix Co was 2024 26.65 % . It decreases by -6.60% lower compared to the previous year.

For Humedix Co, the operating (EBIT) margin of 24.9% is up versus 12.5% a few years ago.

The Humedix Co EBIT Margin history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBIT Margin
Date
EBIT Margin
Jan 1, 2018
16.49 KRW
Jan 1, 2019
15.52 KRW
Jan 1, 2020
16.84 KRW
Jan 1, 2021
12.46 KRW
Jan 1, 2022
27.48 KRW
Jan 1, 2023
24.50 KRW
Jan 1, 2024
26.65 KRW
Jan 1, 2025
24.89 KRW
The Humedix Co EBIT Margin history
YEAREBIT MarginYoY
24.89 %-6.60%
26.65 %+8.77%
24.50 %-10.84%
27.48 %+120.57%
12.46 %-26.00%
16.84 %+8.47%
15.52 %-5.89%
16.49 %-27.27%
22.68 %-5.11%
23.90 %-28.34%
33.35 %+21.41%
27.47 %+8,487.64%
0.32 %+305.55%
0.08 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Humedix Co Stock analysis

What does Humedix Co do? Humedix Co Ltd, identified by the ticker symbol 200670.KQ and ISIN KR7200670008, is a South Korean enterprise operating within the health care sector, specifically in the pharmaceuticals industry. Headquartered in Seongnam, the company has established itself as a specialized manufacturer and distributor of medical devices and therapeutic products. The firm's core business activities revolve around the production and sale of hyaluronic acid-based medical devices, which are widely utilized in various clinical applications, as well as specialized products designed for the treatment of arthritis. This focus on hyaluronic acid highlights the company's commitment to addressing significant health challenges related to joint health and mobility, catering to a growing demographic concerned with degenerative joint conditions. The company maintains a workforce of 338 full-time employees, reflecting its operational scale and capacity to manage both domestic and international supply chains. Humedix achieved a significant milestone in its corporate history by conducting its initial public offering on December 26, 2014. This event marked the company's entry into the public markets, providing it with increased visibility and access to capital for potential expansion and research initiatives. Since its public listing, Humedix has continued to refine its product portfolio and strengthen its market presence. Geographically, the company distributes its products not only within the domestic South Korean market but also extends its reach to overseas markets. This dual-market strategy allows Humedix to diversify its revenue streams and mitigate risks associated with regional economic fluctuations. By serving both local and international customers, the company leverages its manufacturing capabilities to meet diverse regulatory and consumer demands across different regions. The headquarters in Seongnam serves as the central hub for its administrative, research, and distribution operations, ensuring efficient coordination of its business activities. Through its dedicated efforts in developing hyaluronic acid-based solutions, Humedix Co Ltd continues to play a role in the broader health care ecosystem, providing essential medical devices and treatments that improve patient outcomes. The company's website, http://www.humedix.com/, serves as a primary resource for stakeholders seeking further information about its products, corporate governance, and financial performance. As the health care landscape evolves, Humedix remains focused on its core competencies in pharmaceutical manufacturing and medical device distribution, aiming to sustain growth and innovation in its specialized field. Humedix Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Humedix Co stock

EBIT Margin (Operating Margin) of Humedix Co is 24.89 % in 2025.

EBIT Margin (Operating Margin) of Humedix Co changed from 26.65 % to 24.89 %, representing a -6.60% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EBIT Margin (Operating Margin) Humedix Co since 2006 – with annual values, charts, and detailed analysis.

EBIT Margin measures operating profitability as a percentage of revenue. It shows how much profit a company makes from operations before interest and taxes.

A 'good' varies by industry and company stage. On Eulerpool, you can compare EBIT Margin (Operating Margin)'s Humedix Co with sector peers and the industry average to assess whether it is attractive.

To evaluate EBIT Margin (Operating Margin)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for EBIT Margin (Operating Margin).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Margins — Humedix Co

All Key Metrics — Humedix Co